Key Highlights
- $73M Series B funding led by IVP, with support from Index Ventures and Kindred Capital.
- Total funding exceeds $100M, accelerating Cradle’s vision for global AI-driven protein engineering.
- Cradle’s AI models enable 1.2-12x faster R&D and up to 90% cost reductions.
- Trusted by industry leaders like Novo Nordisk, Johnson & Johnson, Novonesis, and Grifols.
- New Chief Commercial Officer Sam Partovi joins as the 40th team member to drive growth.
Source: Direct
Notable Quote
- “Biology is one of the domains where generative AI can have the biggest positive impact, and Cradle is leading the way with its pioneering approach to protein design as a digital service.” — Alex Lim, General Partner at IVP
SoHC's Take
Cradle’s innovative approach to AI-powered protein engineering is a game-changer in life sciences. By leveraging generative AI and continuous learning, the platform offers unprecedented efficiency and accuracy in developing protein-based solutions. The funding milestone highlights investor confidence in Cradle’s ability to transform R&D processes across diverse sectors, from therapeutics to sustainable materials. With its strong customer base and clear roadmap for scaling operations, Cradle is poised to reshape how science tackles some of the world’s most pressing challenges.
